Physician profile
Bradley Wiley
NPI 1013950070
$10,659.38
in general payments reported to CMS, 2019-2025
38 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,941 · 2020: $1,438 · 2021: $1,000 · 2022: $1,651 · 2023: $1,596 · 2024: $1,924 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,628.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,549.66 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,261.50 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $949.67 | 2019-2023 | Jardiance |
| Pfizer INC. | $864.35 | 2019-2025 | |
| Novo Nordisk INC | $798.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $634.62 | 2022-2025 | Freestyle Libre |
| Glaxosmithkline, LLC. | $526.61 | 2020-2025 | Shingrix, Arexvy |
| Amgen INC. | $379.85 | 2019-2024 | Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $362.11 | 2019-2022 | |
| Dexcom, INC. | $354.27 | 2021-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $333.05 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $253.73 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $243.36 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $198.32 | 2019-2022 | |
| Genzyme Corporation | $198.31 | 2023-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Wiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.